Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

  • Be the first to comment

  • Be the first to like this


  1. 2. Largest pharmaceutical company out of India with global reach and competencies across the value chain
  2. 5. Rationalizing Healthcare costs a key priority for Governments Emerging Markets: accelerating branded generics Key Growth Drivers
  3. 8. Perhaps the largest front-end in the generic industry Ground presence in 49 countries; products sold in 125 North America & Japan Europe Other Emerging Markets BRICS <ul><li>No. 1 in India </li></ul><ul><li>Large, reputed player in CIS; growing rapidly </li></ul><ul><li>No. 6 in Brazil </li></ul><ul><li>No. 5 in S. Africa </li></ul><ul><li>43/54 countries in Africa </li></ul><ul><li>Latan & Asia Pacific: long standing presence; good understanding; robust businesses </li></ul><ul><li>Pioneer entrant from India </li></ul><ul><li>Strong local presence </li></ul><ul><li>Canada: New market, growing rapidly </li></ul><ul><li>Well established </li></ul><ul><li>23/25 EU markets </li></ul><ul><li>No. 1 Generic player in Romania </li></ul>
  4. 9. Revenue Profile
  5. 10. $ Million Extensive ground presence, especially in high-growth brand-driven emerging markets * 2009 Guidance is based on INR-USD exchange rate of 50.5
  6. 11. $ Million Favourable Market Mix <ul><li>Revenues spread across geographies </li></ul><ul><li>Growing share of high growth, sustainable branded business in Emerging Markets </li></ul><ul><li>Substantial presence in regulated, western markets: high volume base business </li></ul>=> Stability and sustainability of profits
  7. 12. One of the largest ANDA and FTF Pipeline
  8. 13. Innovator Market Size 62 Other ANDAs 16 P-IV FTFs $ 22 Billion $ 28 Billion
  9. 14. Proven R&D and IP capabilities for developed markets => large base business + consistent upsides through Para-IV FTFs Ability to monetize FTF opportunities… Molecule Innovator Market Size Status Year Simvastatin* Merck (Zocor) $ 0.5 Bn Launched 2006 Pravastatin* BMS (Pravachol) $ 0.2 Bn Launched 2007 Sumatriptan GSK (Imitrex) $ 1.0 Bn Launched 2008 Valacyclovir GSK (Valtrex) $ 1.3 Bn Settled 2009 Esomeprazole^ AZN (Nexium) $ 5.5 Bn Settled 2009-14 Tamsulosin BI**/Astellas (Flomax) $ 1.2 Bn Settled 2010 Atorvastatin Pfizer (Lipitor) $ 8.0 Bn Settled 2011
  10. 15. * Proof of Concept Drug Discovery Programme <ul><li>Phase-III Clinical trials started for Arterolane </li></ul><ul><li>Arterolane is a novel synthetic anti-malarial drug </li></ul><ul><li>Potential to mitigate problems with current standard-of-care which is plant based </li></ul><ul><li>Merck Alliance </li></ul><ul><li>Drug Discovery & Clinical Development through Phase II clinical trials </li></ul><ul><li>Therapeutic area focus of anti-bacterial & anti-fungal drug candidates </li></ul><ul><li>> $ 100 Mn in milestone and significant royalties on commercialization </li></ul>
  11. 16. A platform for new growth opportunities <ul><li>GSK Alliance </li></ul><ul><li>Phase-I human clinical trials initiated for a Respiratory Inflammation molecule </li></ul><ul><li>Take leads beyond candidate selection to POC* in man </li></ul><ul><li>Therapeutic area focus of AI & Metabolic, Respiratory & Oncology </li></ul><ul><li>> $ 100 Mn in milestone and double digit royalties on commercialization </li></ul>Drug Discovery Programme
  12. 17. Recent US Developments – Multipronged Strategy We are working on all fronts to swiftly resolve all matters and minimize transient business impact <ul><li>Realigning Supply Chain </li></ul><ul><li>Sourcing opportunities </li></ul><ul><li>Site transfers </li></ul>Engaged in constructive dialogue with authorities Resolving the USFDA Import Alert and AIP is the highest priority Warning Letters & Import Alert on 30 products from 2 Indian facilities; AIP Working with USFDA for an early solution Strengthening processes in Manufacturing
  13. 18. Prepared for the future
  14. 19. Pharma & Business Imperatives… With increasing pressures in the developed world, high-growth emerging markets necessitate higher focus
  15. 20. … Are Forcing a Rethink of Established Models Going forward, will “pure-play” models be able to cater to shareholder expectations? Generic Companies
  16. 21. Combining Capabilities will Drive Growth <ul><li>Access to high growth, high volume markets </li></ul><ul><li>Access to low cost R&D and Manufacturing </li></ul><ul><li>Access to proprietary products </li></ul><ul><li>Access to advanced competencies and capabilities </li></ul><ul><li>Product portfolio spanning market segments </li></ul><ul><li>Wider reach </li></ul><ul><li>De-risked business model </li></ul>Increasing trend of leveraging both models
  17. 22. Strategic Alliance <ul><li>Daiichi Sankyo is now the majority shareholder </li></ul><ul><li>Synergies start flowing in with launch of Olvance in India, an innovative product of Daiichi Sankyo </li></ul><ul><li>More innovative product launches to follow in emerging markets </li></ul>Impact on Ranbaxy <ul><li>Strengthens Balance Sheet </li></ul><ul><ul><li>Cash Infusion of Rs. 35,849 Million </li></ul></ul><ul><ul><li>Book Value of Shares increases from Rs. 75 (Dec’07) to Rs. 102 (Dec’08) </li></ul></ul><ul><li>Fast track growth in world’s #2 pharma market </li></ul><ul><li>Proprietary product flow for our strong branded business in emerging markets </li></ul><ul><li>Potential benefits in R&D and Manufacturing </li></ul>
  18. 23. Ranbaxy:: Surging Ahead Synergies of being a part of Daiichi Sankyo will upscale all above
  19. 24. In Summary <ul><li>A vertically integrated global pharmaceutical Company </li></ul><ul><li>Presence across all key developed & emerging markets </li></ul><ul><li>Strong distribution network & brand building capabilities </li></ul><ul><li>Cost efficient India based Research & Development and Manufacturing </li></ul><ul><li>Robust generic product flow </li></ul><ul><li>New high growth specialty segments </li></ul><ul><li>Focus on NCE research </li></ul>
  20. 25. Thank You